AURX (Nuo Therapeutics) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nuo Therapeutics 3-Year Dividend Growth Rate?

Nuo Therapeutics's Dividends per Share for the three months ended in Sep. 2024 was $0.00.

The historical rank and industry rank for Nuo Therapeutics's 3-Year Dividend Growth Rate or its related term are showing as below:

AURX's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 13.2
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Nuo Therapeutics's Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Nuo Therapeutics's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Nuo Therapeutics's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Nuo Therapeutics's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuo Therapeutics's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's 3-Year Dividend Growth Rate falls into.

Nuo Therapeutics 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Nuo Therapeutics (OTCPK:AURX) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Nuo Therapeutics's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-0.01
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuo Therapeutics 3-Year Dividend Growth Rate Related Terms>

Nuo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuo Therapeutics Inc (OTCPK:AURX) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

8285 El Rio Street, Suite 190, Houston, TX, USA, 77054

Website

https://www.nuot.com

Nuo Therapeutics Inc is a regenerative therapies company focused on developing and marketing products for chronic wound care primarily within the U.S. Company's commercialize innovative cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The company derives revenues from the sale of the Aurix product to customers consisting of primarily hospital outpatient wound care clinics and other private practice physicians treating chronic wounds.

Executives

Charles E Sheedy	10 percent owner	TWO HOUSTON CENTER, SUITE 2907, HOUSTON TX 77010
David Emerson Jorden	director, officer: CEO, CFO	2635 TECHNOLOGY FOREST BLVD., THE WOODLANDS TX 77381
Lawrence Atinsky	director	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
C Eric Winzer	director
Paul Mintz	director	C/O NUO THERAPEUTICS INC., 207A PERRY PARKWAY, SUITE 1, GAITHERSBURG MD 20877
Peter Clausen	officer: CSO	11204 JEFFRO COURT, IJAMSVILLE MD 21754
Scott M. Pittman	director	3683 JOHN NASH BLVD., BLUEFIELD WV 24701
Boyalife Investment Fund I, Inc.	10 percent owner	2453 S. ARCHER AVE., SUITE B, CHICAGO IL 60616
Dean Tozer	officer: CHIEF COMMERCIAL OFFICER	C/O ADVANCED BIOHEALING, INC., 36 CHURCH LANE, WESTPORT CT 06880
Steven A Shallcross	officer: SEE REMARKS	C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Aldagen Holdings, Llc	10 percent owner, other: May be part of a 13(d) group	C/O THOMAS A. ALLEN, ESQ., 4101 LAKE BOONE TRAIL, STE 300, RALEIGH NC 27607
Kathryne Carr	10 percent owner, other: May be part of a 13(d) group	315 OLD IVY WAY, SUITE 101, CHARLOTTESVILLE VA 22903
William W Brooke	10 percent owner, other: May be part of a 13(d) group	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Guercio Joseph Del	director	C/O CLARK INVESTMENTS, 7500 OLD GEORGETOWN ROAD, SUITE 620, BETHESDA MD 20814
B. Jefferson Clark	10 percent owner, other: May be part of a 13(d) group	C/O ALDAGEN, INC., 2810 MERDIAN PARKWAY, SUITE 148, DURHAM NC 27713